NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment
Open Access
- 1 January 2011
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 13 (6), R196-9
- https://doi.org/10.1186/ar3526
Abstract
Muckle-Wells syndrome (MWS) is an inherited autoinflammatory disease characterized by fever, rash, arthralgia, conjunctivitis, sensorineural deafness and potentially life-threatening amyloidosis. The NLRP3/CIAS1 E311K mutation caused a heterogeneous phenotype of MWS in a large family. This study analyzes the clinical spectrum, patterns of inflammatory parameters and reports on response to treatment. A total of 42 patients and family members were screened for the presence of the NLRP3 mutation. Clinical symptoms were reviewed in all family members. Classical (erythrocyte sedimentation rate (ESR, C-reactive protein (CRP)) and novel MWS inflammatory markers (serum amyloid A (SAA), cytokines, cytokine receptor levels) were determined. Patients were treated with the IL-1 inhibitors Anakinra or Canakinumab. All 13 clinically affected patients were heterozygous carriers of the amino acid substitution p.Glu311Lys/E311K encoded by exon 3 of the NLRP3 gene, but none of the healthy family members. Disease manifestations varied widely. Except for one child, all carriers suffered from hearing loss and severe fatigue. TNF-α, IL-6, TNF-RI, and TNF-RII levels as well as SAA were elevated in three, two, one, six and ten patients, respectively. Both clinical and laboratory parameters responded quickly and sustainedly to treatment with Anakinra or Canakinumab. The NLRP3 E311K mutation is associated with a heterogeneous clinical spectrum, which may expand the view on MWS presentation. The leading symptom was hearing loss. Pericarditis, a rare but severe clinical feature of MWS, was diagnosed in three patients. One patient had a severe course, which led to renal failure secondary to amyloidosis. IL-1 inhibition leads to rapid and sustained improvement of symptoms.This publication has 25 references indexed in Scilit:
- Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in FranceAnnals Of The Rheumatic Diseases, 2010
- Risk factors for severe Muckle‐Wells syndromeArthritis & Rheumatism, 2010
- Long‐term efficacy of the interleukin‐1 receptor antagonist anakinra in ten patients with neonatal‐onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndromeArthritis & Rheumatism, 2009
- Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS)Expert Opinion on Biological Therapy, 2009
- The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin modelArthritis & Rheumatism, 2007
- Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients – expanding phenotype of CIAS1 related autoinflammatory syndromeEuropean Journal of Haematology, 2004
- Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinraArthritis & Rheumatism, 2004
- Genomic-based therapy: Targeting interleukin-1 for autoinflammatory diseasesArthritis & Rheumatism, 2004
- Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosisArthritis & Rheumatism, 2002
- Genetic Linkage of the Muckle-Wells Syndrome to Chromosome 1q44American Journal of Human Genetics, 1999